Prelude Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-14,928
| Closed | -$129K | – | 1505 |
|
|
2024
Q2 | $129K | Hold |
14,928
| – | – | 0.01% | 977 |
|
|
2024
Q1 | $131K | Hold |
14,928
| – | – | 0.01% | 1064 |
|
|
2023
Q4 | $111K | Hold |
14,928
| – | – | 0.01% | 889 |
|
|
2023
Q3 | $86.1K | Buy |
+14,928
| New | +$86.1K | 0.01% | 862 |
|
|
2023
Q2 | – | Sell |
-14,929
| Closed | -$110K | – | 1326 |
|
|
2023
Q1 | $110K | Hold |
14,929
| – | – | 0.01% | 846 |
|
|
2022
Q4 | $99.8K | Hold |
14,929
| – | – | 0.01% | 935 |
|
|
2022
Q3 | $153K | Hold |
14,929
| – | – | 0.01% | 1090 |
|
|
2022
Q2 | $182K | Sell |
14,929
-2,164
| -13% | -$26.4K | 0.01% | 1116 |
|
|
2022
Q1 | $362K | Buy |
17,093
+4,542
| +36% | +$96.2K | 0.01% | 791 |
|
|
2021
Q4 | $755K | Buy |
12,551
+11,729
| +1,427% | +$706K | 0.02% | 578 |
|
|
2021
Q3 | $77K | Buy |
+822
| New | +$77K | ﹤0.01% | 1169 |
|